tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Roche Holding AG (OtherRHHVF) and Bone Biologics (BBLG)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Argenx Se (ARGXResearch Report), Roche Holding AG (RHHVFResearch Report) and Bone Biologics (BBLGResearch Report).

Argenx Se (ARGX)

Wells Fargo analyst Derek Archila maintained a Buy rating on Argenx Se today and set a price target of $469.00. The company’s shares closed last Monday at $361.05.

According to TipRanks.com, Archila is a 3-star analyst with an average return of 0.8% and a 39.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Prometheus Biosciences, and Blueprint Medicines.

Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $433.94.

See today’s best-performing stocks on TipRanks >>

Roche Holding AG (RHHVF)

In a report released today, Michael Leuchten from UBS maintained a Hold rating on Roche Holding AG, with a price target of CHF328.00. The company’s shares closed last Monday at $325.70.

Leuchten has an average return of 7.1% when recommending Roche Holding AG.

According to TipRanks.com, Leuchten is ranked #2191 out of 7987 analysts.

Roche Holding AG has an analyst consensus of Moderate Buy, with a price target consensus of $372.48, a 16.2% upside from current levels. In a report issued on October 4, J.P. Morgan also maintained a Hold rating on the stock with a CHF300.00 price target.

Bone Biologics (BBLG)

Bone Biologics received a Buy rating and a $2.25 price target from EF Hutton analyst Constantine Davides today. The company’s shares closed last Monday at $0.53, close to its 52-week low of $0.50.

According to TipRanks.com, Davides has 0 stars on 0-5 stars ranking scale with an average return of -29.3% and a 25.0% success rate. Davides covers the Healthcare sector, focusing on stocks such as Pasithea Therapeutics Corp, Electromed, and BioVie.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bone Biologics.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ARGX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles